X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (138) 138
humans (127) 127
diabetes mellitus, type 2 - drug therapy (111) 111
type 2 diabetes (109) 109
endocrinology & metabolism (97) 97
hypoglycemic agents - therapeutic use (85) 85
once-daily lixisenatide (85) 85
open-label (80) 80
once-daily liraglutide (77) 77
double-blind (63) 63
glycemic control (63) 63
diabetes (62) 62
liraglutide (60) 60
glucagon-like peptide-1 (56) 56
basal insulin (55) 55
insulin (52) 52
exenatide (49) 49
female (47) 47
male (47) 47
placebo-controlled trial (46) 46
glucagon (44) 44
glucagon-like peptide-1 receptor - agonists (44) 44
metformin (43) 43
hypoglycemic agents - administration & dosage (40) 40
pharmacology & pharmacy (40) 40
glucose (38) 38
middle aged (38) 38
diabetes mellitus, type 2 - blood (37) 37
hypoglycemia (37) 37
hypoglycemic agents - adverse effects (37) 37
peptides - therapeutic use (37) 37
type 2 diabetes mellitus (37) 37
lixisenatide (35) 35
glp-1 receptor agonist (34) 34
treatment outcome (34) 34
diabetes mellitus (33) 33
drug therapy, combination (33) 33
safety (33) 33
diabetes therapy (32) 32
hypoglycemia - chemically induced (29) 29
aged (28) 28
beta-cell function (28) 28
care and treatment (28) 28
clinical trials (27) 27
dextrose (27) 27
efficacy (27) 27
internal medicine (27) 27
type-2 diabetes-mellitus (27) 27
blood glucose - drug effects (26) 26
medicine, general & internal (26) 26
drug therapy (25) 25
glucagon-like peptide 1 - analogs & derivatives (25) 25
hypoglycemic agents (25) 25
insulin - therapeutic use (25) 25
fixed-ratio combination (24) 24
glycosylated hemoglobin (24) 24
insulin glargine (24) 24
diabetes mellitus, type 2 - metabolism (23) 23
glucagon-like peptide-1 receptor (23) 23
blood glucose - metabolism (22) 22
glp-1 (22) 22
glp-1 receptor agonists (22) 22
improves glycemic control (22) 22
receptor agonist lixisenatide (22) 22
adult (21) 21
body weight (21) 21
metformin-treated patients (21) 21
peptides - adverse effects (21) 21
analysis (20) 20
glycated hemoglobin a - analysis (20) 20
human glp-1 analog (20) 20
twice-daily exenatide (20) 20
drug administration schedule (19) 19
exenatide twice (19) 19
glycated hemoglobin a - metabolism (19) 19
hemoglobin (19) 19
medicine & public health (19) 19
peptides (19) 19
randomized controlled trials as topic (19) 19
receptors, glucagon - agonists (19) 19
risk factors (19) 19
therapy (19) 19
hypoglycemic agents - pharmacology (18) 18
insulin - administration & dosage (18) 18
obesity (18) 18
peptides - administration & dosage (18) 18
type-2 (18) 18
glucagon-like peptide 1 - therapeutic use (17) 17
hyperglycemia (17) 17
research (17) 17
diabetes mellitus, type 2 - complications (16) 16
drug-naive patients (16) 16
health aspects (16) 16
patients (16) 16
dulaglutide (15) 15
to-target trial (15) 15
dipeptidyl peptidase-4 inhibitor (14) 14
glucagon-like peptide 1 (14) 14
hyperglycemia - prevention & control (14) 14
liraglutide - therapeutic use (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMJ : British Medical Journal, ISSN 0959-8138, 10/2015, Volume 351, p. h5364
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2015, Volume 17, Issue 11, pp. 1056 - 1064
Journal Article
Drugs, ISSN 0012-6667, 12/2011, Volume 71, Issue 17, pp. 2347 - 2373
Liraglutide (Victoza®) is a subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and used as an... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Adis-Drug-Evaluations | Type-2-diabetes-mellitus | Liraglutide | GLP-1 | pharmacodynamics | HUMAN GLP-1 ANALOG | incretin therapies | ONCE-DAILY LIRAGLUTIDE | BETA-CELL FUNCTION | TWICE-DAILY EXENATIDE | glucagon-like peptide 1 analogues | GLUCAGON-LIKE PEPTIDE-1 | IMPROVES GLYCEMIC CONTROL | tolerability | type 2 diabetes mellitus | pharmacokinetics | DOUBLE-BLIND | REDUCES BODY-WEIGHT | PHARMACOLOGY & PHARMACY | OPEN-LABEL TRIAL | TOXICOLOGY | bodyweight loss | ACUTE-PANCREATITIS | therapeutic use | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Glucagon-Like Peptide 1 - administration & dosage | Hypoglycemic Agents - economics | Glucagon-Like Peptide 1 - analogs & derivatives | Humans | Glucagon-Like Peptide 1 - economics | Glucagon-Like Peptide 1 - pharmacology | Clinical Trials as Topic | Hypoglycemic Agents - pharmacology | Hypoglycemic Agents - administration & dosage | Glucagon-Like Peptide 1 - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Weight loss | Research | Drug therapy | Health aspects | Diabetes therapy
Journal Article
Journal Article
Journal Article
Journal Article
Frontiers in Endocrinology, ISSN 1664-2392, 2019, Volume 10
The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects on glycemic control and body weight regulation, led to efforts to... 
Type 2 diabetes | Obesity | GLP-1 | Albumin | Semaglutide | Once-weekly | Liraglutide | liraglutide | once-weekly | GLYCEMIC CONTROL | HUMAN SERUM-ALBUMIN | FOOD-INTAKE | ANALOG LIRAGLUTIDE | ONCE-DAILY LIRAGLUTIDE | OPEN-LABEL | FATTY-ACIDS | type 2 diabetes | GLUCAGON-LIKE PEPTIDE-1 | albumin | ENDOCRINOLOGY & METABOLISM | GLP-1 RECEPTOR AGONIST | BETA-CELL MASS | obesity | semaglutide | Diabetes therapy
Journal Article